Silverback Therapeutics (SBTX) Competitors $9.11 -0.54 (-5.60%) As of 10/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock SBTX vs. ZYME, CALT, NLTX, AVTE, BIOA, VIRI, WHWK, SPRB, LITS, and ELYMShould you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), Neoleukin Therapeutics (NLTX), Aerovate Therapeutics (AVTE), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Spruce Biosciences (SPRB), Lite Strategy (LITS), and Eliem Therapeutics (ELYM). Silverback Therapeutics vs. Its Competitors Zymeworks Calliditas Therapeutics AB (publ) Neoleukin Therapeutics Aerovate Therapeutics BioAge Labs Virios Therapeutics Whitehawk Therapeutics Spruce Biosciences Lite Strategy Eliem Therapeutics Zymeworks (NASDAQ:ZYME) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation. Which has more volatility & risk, ZYME or SBTX? Zymeworks has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Is ZYME or SBTX more profitable? Silverback Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -59.96%. Zymeworks' return on equity of -21.59% beat Silverback Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-59.96% -21.59% -16.52% Silverback Therapeutics N/A -29.62%-28.20% Do institutionals & insiders believe in ZYME or SBTX? 92.9% of Zymeworks shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer ZYME or SBTX? In the previous week, Zymeworks had 10 more articles in the media than Silverback Therapeutics. MarketBeat recorded 11 mentions for Zymeworks and 1 mentions for Silverback Therapeutics. Zymeworks' average media sentiment score of 0.28 beat Silverback Therapeutics' score of 0.00 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 1 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Silverback Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ZYME or SBTX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 2.75Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation & earnings, ZYME or SBTX? Silverback Therapeutics has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$122.87M10.85-$122.69M-$0.97-18.29Silverback TherapeuticsN/AN/A-$89.48M-$2.42-3.76 SummaryZymeworks beats Silverback Therapeutics on 10 of the 14 factors compared between the two stocks. Get Silverback Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBTX vs. The Competition Export to ExcelMetricSilverback TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$328.49M$1.08B$6.25B$10.67BDividend YieldN/A4.84%5.72%4.82%P/E Ratio-3.761.4930.9830.65Price / SalesN/A30.84561.02174.40Price / CashN/A17.6337.0861.44Price / Book1.238.0012.056.61Net Income-$89.48M-$7.35M$3.33B$277.10M7 Day Performance-9.35%2.49%1.89%2.55%1 Month Performance-8.35%29.62%7.71%3.77%1 Year Performance-38.32%-14.24%56.33%33.05% Silverback Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBTXSilverback TherapeuticsN/A$9.11-5.6%N/A-37.3%$328.49MN/A-3.7683News CoverageHigh Trading VolumeZYMEZymeworks0.1682 of 5 stars$17.93-2.1%N/AN/A$1.35B$76.30M-18.48460News CoverageAnalyst ForecastCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180NLTXNeoleukin TherapeuticsN/A$32.16+10.8%N/A-40.4%$302.24MN/A-10.3490Gap UpHigh Trading VolumeAVTEAerovate TherapeuticsN/A$10.00+6.7%N/A-86.5%$289.85MN/A-3.3420High Trading VolumeBIOABioAge Labs0.119 of 5 stars$5.30-1.1%N/AN/A$190.01MN/A0.00N/AVIRIVirios TherapeuticsN/A$6.19+7.5%N/A+36.1%$119.21MN/A-22.935WHWKWhitehawk Therapeutics1.3029 of 5 stars$2.28-14.3%N/AN/A$107.45M$21.60M-38.0021News CoveragePositive NewsAnalyst ForecastSPRBSpruce Biosciences1.1042 of 5 stars$129.54-12.6%$140.83+8.7%+203.7%$72.54M$4.91M-1.5020Trending NewsAnalyst ForecastAnalyst RevisionLITSLite StrategyN/A$1.95-1.5%N/AN/A$69.53MN/A-0.41100Positive NewsAnalyst ForecastELYMEliem TherapeuticsN/A$2.32+20.2%N/A-57.2%$69.03MN/A-4.389Gap UpHigh Trading Volume Related Companies and Tools Related Companies ZYME Alternatives CALT Alternatives NLTX Alternatives AVTE Alternatives BIOA Alternatives VIRI Alternatives WHWK Alternatives SPRB Alternatives LITS Alternatives ELYM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBTX) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SBTX Stock Alerts